Cardio Diagnostics Holdings Inc. - Common stock (CDIO)
1.1200-0.1400(-11.11%)
Cardio Diagnostics Holdings Inc. is a healthcare company focused on advancing personalized cardiovascular medicine through innovative diagnostic solutions. The company develops and commercializes cutting-edge technologies aimed at improving heart health management by offering comprehensive insights into individual cardiovascular risks. By leveraging advanced analytics and proprietary testing methodologies, Cardio Diagnostics seeks to empower healthcare providers and patients with actionable data to enhance decision-making and optimize treatment strategies for cardiovascular diseases. Their mission is to enhance patient outcomes and revolutionize the way cardiovascular health is understood and managed.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company’s PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from the Centers for Medicare & Medicaid Services (CMS). Following the preliminary pricing determination made by CMS in August 2024, CMS finalized the ‘gapfill’ pricing determination for both PrecisionCHD and Epi+Gen CHD. This decision will be effective for claims with dates of service on or after January 1, 2025, and will allow Medicare contractors to determine pricing for PrecisionCHD and Epi+Gen CHD based on actual cost data from Cardio Diagnostics. The Medicare contractors will report to CMS preliminary gapfill pricing for calendar year 2025 by April 1, 2025.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, today announced it will sponsor and exhibit at the Florida Association of ACOs (FLAACOs) 2024 Annual Fall Conference, taking place in Orlando, FL, from November 20-22, 2024. The conference, hosted at the JW Marriott Orlando Bonnet Creek, brings together healthcare leaders and organizations focused on advancing value-based care models nationwide.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company today announced that the Company’s PrecisionCHD and Epi+Gen CHD tests have received preliminary pricing determinations from the Centers for Medicare & Medicaid Services (CMS). This determination represents a crucial step toward securing Medicare reimbursement, enabling access to the Company’s affordable, innovative, and highly scalable blood tests aimed at improving the risk assessment, diagnosis, management and monitoring of coronary heart disease (CHD) for Medicare patients.
CDIO stock results show that Cardio Diagnostics Hldgs beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-powered precision cardiovascular medicine, today announced the launch of its redesigned website at CDIO.AI. This new site emphasizes the Company's AI-first approach and innovative scalable solutions for the prevention, detection and management of cardiovascular disease, which is the leading cause of death globally. This site also streamlines access to critical information and resources for investors, partners, patients, providers, and other key stakeholders.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company’s clinical blood test, Epi+Gen CHD is now available at Family Medicine Specialists’ (FMS) retail clinical location at the Meijer Supercenter in McHenry, Illinois.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company will sponsor a booth and showcase its groundbreaking cardiovascular solutions at the 2024 Onsite Employee Health Clinics Forum, taking place in Chicago, IL, from June 27-28, 2024. The Forum attracts senior executives from various healthcare sectors, including hospitals, health systems, health plans, and employer plans. The event is focused on enabling employers to build, launch, and optimize onsite clinical care facilities that are innovative and effective for their employees.
CDIO stock results show that Cardio Diagnostics Hldgs missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Mayumi Kitakata, a Tokyo resident, uses the AI-driven app CatsMe! to monitor the health of her aging cat, reflecting the growing trend of AI in pet healthcare.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), a leader in AI-driven precision cardiovascular medicine, today announced the successful completion of its System and Organization Controls (SOC) 2 Type I audit, achieving compliance with the leading industry standards for customer data security. This milestone underscores the Company’s unwavering commitment to the highest data security standards.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, today announced its participation in the Clinical Laboratory Fee Schedule (CLFS) Annual Meeting on June 25, 2024. At this meeting hosted by the Centers for Medicare & Medicaid Services (CMS), the Company will recommend pricing for its innovative clinical tests to be considered for Medicare payment under the CLFS for calendar year 2025.
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, announced today that the Company’s clinical blood tests, Epi+Gen CHD and PrecisionCHD, are now available at Family Medicine Specialists’ (FMS) newest clinical location at the Walmart Supercenter in Round Lake Beach, Illinois. FMS is a leading primary care and risk-bearing provider in Northern Illinois and in December 2023, launched the ongoing Heart Attack Prevention Initiative for at least 1,200 of their BlueCross BlueShield and other health plan patients. This launch in a retail healthcare setting is an expansion to existing and new patients in the area.
